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1. Introduction  
Integrated Positron Emission Tomography Computed Tomography (PET/CT) is becoming 
an important tool for clinical investigation with increase clinical utilization. Technology 
evolution has brought tremendous improvement in lesion detection by integrating 
morphological and functional informations in a single study. Improved technical 
specification for CT and PET camera is translated into shorter time spent in image 
acquisition and reconstruction with improved PET temporal resolution. Both systems 
complement each other in improving diagnostic capabilities by enabling accurate lesion 
localization unlike stand alone PET or CT system .  
A combined PET/CT system involves the use of a full-ring detector PET scanner with a 
multi-detector helical CT scanner in combination, allowing the PET scan to be acquired 
sequentially after the CT scan. The images are then fused to give a precise localization of 
PET-positive lesions. When integrated PET/CT system was initially introduced, CT scan 
was performed using low dose exposure without intravenous contrast administration.  
This new integrated technology imaging diagnostic system improved lesion detectability, 
localization, and characterization in up to 30% of 204 cases as demonstrated by Rachel and 
her colleague (1). The greatest impact was in abdominal and pelvic diagnostic 
interpretations than any other sites.  
To optimize the diagnostic capability of both systems during an integrated PET/CT study, 
variations to the basic CT practice has been employed.(2). In addition to useful diagnostic 
informations obtained, the advantage of advance CT protocol can be observed in cases 
where lesions are non PET-avid, and alternative diagnostic imaging study is needed. Thus, 
higher diagnostic CT quality performed during integrated PET/CT study will avoid the 
hassle for a separate diagnostic CT appointment.  
This chapter will highlight the advantages of contrasted CT over low dose CT in a 
contemporaneous integrated FDG PET/CT study. The capability of both modalities would 
be optimized if such technique is employed . The technical aspects of multi detector CT and 
PET and the specifications are discussed elsewhere.  
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2. PET technique – Basic and advance 
2.1 Basic PET technique  
PET is a nuclear imaging technique which detects abnormal tissues with the help of 
molecular imaging probe like flurodeoxyglucose (FDG), dopa, fluoroethylcholine (FLT) and 
fluoroethylthymidine (FET). These probes can be tagged with radioisotopes like 18-Fluorine 
(18F) and carbon (11C ,12C). These unstable isotopes while emitting beta plus (β+) rays will 
enable the PET camera to localize the highest decaying activity in the body. The process can 
be captured and image. However, due to poor resolution of PET camera, a standalone PET 
system yields poor lesion localization. To improve the resolution, transmission from 
Germanium-68 isotope was utilized for attenuation correction but the technique is time 
consuming. All new PET systems are now improved by incorporation with a CT system. 
The CT parameters are used for attenuation correction of PET images. The new integrated 
system is capable in delivering higher quality images with improved resolution (Figure 1) . 
The time spent for each examination is shorter in comparison to using the conventional old 
PET system.  
 
    
                                            (a)                (b) 
Fig. 1. Coronal view of PET image in grey scale demonstrating non attenuation corrected 
image (a) and attenuation corrected image (b) using CT parameters. 
The widely recommended protocol for a PET study is intravenous injection of 8-12mci of 
18F-FDG isotope after ensuring that the patient is fasting by obtaining fasting blood sugar. 
Prior to intravenous administration of isotope, the height and weight of the patient will also 
be recorded. These essential parameters are important for accurate calculation of 
standardized uptake value (SUV), a recognized method in semiquantifying the FDG uptake 
in avid lesions. PET/CT image acquisition will start after 45 minutes post injection rest to 
ensure good FDG uptake and distribution in the body. Image acquisition will start with a 
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scanogram for planning the study followed by low dose CT from eyes to the thigh with 
exception in cases of melanoma and childrens. Images acquired in 2D or 3D mode with 2-3 
minutes per bed position ending with 5-7 bed positions will depend on the dose of isotope 
injected and size of the patient. Tall patients may require more time to complete the eyes 
and thigh protocol as compared to shorter individuals.  
This recommended basic PET imaging technique is practiced with minor variation from one 
institution to another depending on camera specification and work load.  
2.2 Advance PET technique  
Advance whole body FDG PET study includes delayed or dual- time point imaging 
techniques.  
In delayed PET image acquisition technique, imaging is delayed after 90 minutes following 
an earlier acquisition at 45 minutes (3).Russ et al observed a significant increase in standard 
uptake value (SUV) of liver lesions between early and delayed acquisition (p< 0.001) in 30 
patients without significant reduction in liver background activity between the two studies 
allowing better lesion detection by visual inspection. Delayed phase PET protocol also 
revealed new lesions in 17% of the patients thus improved lesion detectability in primary 
and metastatic liver disease. Thus, the technique may be deemed beneficial in oncology 
work-up to obtain detail information on extension of lesions . 
Another advance PET technique is the dual-time point imaging. The technique has been 
utilized to differentiate inflammatory from malignant lesions (4,5,6). Lesion of inflammatory 
in origin demonstrate peak FDG uptake at approximately 30 minutes post FDG injection. As 
opposed to aggressive malignant lesions which peak is seen much later depending on 
histopathological variation and degree of aggressiveness.  
3. Contrast  Enhanced Computed Tomography (CECT)  
Computed tomography is a diagnostic radiological imaging modality commonly employed 
to assist physicians in the clinical management. CT is a useful tool in cancer staging, 
localizing infection and inflammatory lesions  and evaluation of treatment response. In 
clinical practice, a stand- alone CT system is often the first choice of cross sectional imaging 
modality to be employed in making a diagnosis. This is attributed to its accessibility, fast, 
relatively cheap and its capability in demonstrating morphological abnormalities. In 
addition, CT procedures are somehow standardized and reproducible.  
Technological development focusing on CT helical systems resulted in increased gantry 
speed rotation, increasing number of detector rows, and increased tube outputs to maintain 
adequate signal-to-noise ratio (SNR) leading to improved image resolution. New 
development involving PET systems are now incorporated into multidetector CT with full 
diagnostic capability.  
In this section, we highlight the benefit of using contrast enhanced CT during integrated 
FDG PET/CT study.  
Although low dose CT has been an acceptable norm in PET/CT practice, contrast enhanced 
CT integrated with PET can be considered as the protocol of choice in recent days especially 
if the technique will benefit the patient’s clinical management .  
Advance CT protocol is useful in demonstrating pathology accurately. This can be achieved 
through dynamic and sequential image acquisition protocols to be incorporated into multiplanar 
PET images. The technique is capable in characterizing tumour physiology with improved 
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visual delineation of tumour margins (7). Inflammatory lesions and infection can also be 
highlighted and shall gain advantage from this technique. The new multidetector CT scanners 
can achieve a high temporal resolution in monitoring contrast agent first-pass effects(8).  
Lesion characterization on CT are through morphological changes , homogeneity, size, 
outline, vascularity and adjacent structure involvement. Lesion characterization through 
enhancement properties depends on whether they are hyper or hypovascular in nature as 
different types of lesions enhance differently during each phase of image acquisition. 
 
 Very Low Dose CT Intermediate dose CT Diagnostic CT 
MAs Less 35 40-80mAs >80mAs 
Description 
No oral, rectal, 
intravenous contrast 
Oral and rectal 
contrast may be 
administered 
Oral, rectal , 
intravenous contrast 
administrered 
Table 1. Recommended CT doses during whole body FDG PET/CT study 
There is increasing evidence in the literature to support the incremental benefit of FDG-
PET/ CT in tumour staging and monitoring treatment response. The latest generation of 
PET/CT machines incorporates multi-detector CT allowing diagnostic quality CT images to 
be obtained. As such, CT images acquired during integrated PET/CT examination can be 
used to avoid separate CT examination for staging or treatment response assessment. Low-
dose CT protocols allow attenuation-correction of PET images and accurate anatomical 
localization. However, image quality is compromised with poor resolution and inability to 
exclude an involvement of surrounding organs and vascular structures. Informations 
obtained at visual image interpretation are vital informations to support clinical decisions. It 
is also vital consideration to the non-specificity of fluorodeoxyglucose (FDG) to malignant 
lesions. Some malignancies demonstrate poor or non FDG-avidity. In these circumstances, 
an alternative imaging modality is needed. Integrated diagnostic contrast enhance-CT 
during PET/CT study potentially avoid another CT session which is inconvenient to the 
patient which lead to delay in diagnosis and treatment delivery. This can be avoided if a 
diagnostic CT is integrated concurrently with PET imaging in a single seating.     
A diagnostic CT procedure incorporated in a PET/CT study may comprise either a single 
phase or a multiphase contrast enhanced CT. Image acquisition during a single phase study 
starts 60-80s following bolus intravenous contrast administration at a rate of 2-3 mls/second 
while multiphase CT comprise of arterial, venous and delayed phase CT where images are 
acquired at different time frame.  
During study of patient with suspicious intracranial pathology, physiological high 
intracerebral FDG uptake will mask the visibility of lesions. Contrasted CT image 
acquisition during the study can potentially identify intracranial structural abnormalities 
(figure 2). 
Non invasive CT angiography of cerebral circulation can be a useful technique for 
demonstrating vascular involvement . This technique can be incorporated into a PET/CT 
study mapping the course of nearby vessels. The information is useful in excluding specific 
vascular involvement and choosing the correct vessel for intra arterial embolization 
procedures.  
In head and neck malignancy involving the neck nodes, contrasted CT during FDG PET/CT 
study can provide useful information prior to CT guided histo-pathological sampling 
procedure in establishing the clinical diagnosis.  
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Fig. 2. Single phase contrast enhanced PET CT in a 28-year old man demonstrating subtle 
enhancing intracerebral (black arrows) tuberculosis abcess in the brain.  
In thoracic malignancy , particularly carcinoma of the lungs involving mediastinal nodes, 
contrast enhanced PET/CT study can be a useful technique in affirming T-staging by 
excluding local invasion, guiding invasive interventional tissue sampling procedure by 
avoiding vital structures and characterizing tumour resectability (figure 3).  
A single phase PET/contrast enhance CT can also be carried out in patients with 
mediastinal malignancy including carcinoma of esophagus (figure 4). 
A 4- phase CT technique involves CT image acquisition at different time phases including a 
plain non contrasted study prior to contrast administration , arterial phase (30 seconds delay 
imaging) , venous phase (70-90 seconds delay imaging) and delayed phase (5-10 minutes 
delay imaging ). Technical softwares are usually available in prescribing the protocol 
depending on the type and specification of the equipment. These include smartprep, care-
bolus or bolus tracking. 
CT is a valuable tool in assessing liver pathology. Informations acquired is very useful in 
planning clinical management especially in cases of hepatocellular carcinoma and 
metastasis. A 4- phase CT liver and a single phase CT can be used in the former and latter 
conditions respectively. 
FDG avidity of hepatocellular carcinoma in PET imaging varies. Most of the time they 
demonstrate low avidity except in aggressive tumour sub-types which usually demonstrate 
higher uptake and activity. Similar to metastatic lesions where tumours with tendency to 
develop cystic liver metastasis will demonstrate low FDG avidity than the more aggressive 
solid liver lesions. In the event of non FDG-avid or unidentified malignant liver lesions 
during a PET/CT study, an alternative imaging modality is sought for to help solving the 
clinical diagnosis (figure 5).   
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Fig. 3. FDG PET/CT study of a 56 year old man with carcinoma of the left lung. FDG PET 
study in sagittal (top) and axial (bottom). Top row (a and b) demonstrate PET/CT study with 
intravenous contrast administration and bottom row (c and d) demonstrate FDG PET/CT with 
low dose non contrasted CT. Intravenous contrast sharply delineating tumour outline ( white 
arrow axial CT image) excluding thoracic wall invasion and vascular involvement. 
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Fig. 4. Whole body FDG PET/CT study showing contrast enhanced CT (a,b,c) and non 
contrast enhanced CT(d,e,f) in a patient diagnosed with carcinoma of esophagus. In axial 
and coronal planes (c,f) . Poor definition of descending aortic wall in non enhanced CT was 
solved after giving intravenous contrast administration (white arrow). Contrast enhanced 
CT helped in determining tumour resectability and treatment planning in this patient 
18F-FDG-PET in combination with low dose CT in the evaluation of hepatocellular 
carcinoma has low sensitivity (55%) in comparison to multiphase contrast enhanced CT 
(90%). Since the role of PET in detecting primary carcinoma is limited, contrasted 
multiphase CT during PET/CT study can be a very useful protocol in detecting liver 
pathology (9).  
The accuracy of low dose CT during qualitative assessment of the liver can be jeorpardized 
in cases where the CT value of the lesions fall within the range of normal liver parenchyma. 
In such situation, contrast enhanced CT can delineate these lesions through enhancing 
pattern of normal liver parenchyma against the lower attenuation value of the lesion itself 
rendering visibility of the lesions separable from the normal liver parenchyma (10,11,12, 13).  
The successful use of contrast enhanced CT during PET/CT examination has been clearly 
demonstrated by Patrick VH and his colleagues. In his study, he reported the integration of 
a combined CT-perfusion in FDG PET study without the use of additional contrast media 
compared to a standard contrast enhance PET/CT study in patients with intra abdominal 
malignancy (14). 
CT is more sensitive than FDG-PET in detecting colorectal metastases following neo-
adjuvant therapy. According to Lubezky and his group (15), the sensitivity of CT in 
comparison to FDG PET is 65% versus 49% (n=27; p<0.0001). The lower sensitivity of FDG 
PET in detecting liver metastasis during this time are attributed by various factors including 
post-chemotherapeutic ‘metabolic shutdown’ phenomenon, small size lesions and non FDG 
avidity.  Baseline FDG PET/CT studies prior to neo-adjuvant therapy in colorectal cancer 
patients are known to be mandatory, thus contrast enhanced CT during this time may 
www.intechopen.com
 
Computed Tomography – Clinical Applications 
 
300 
deemed appropriate. From the study conducted by Lubezky, the technique is obviously 
beneficial in demonstrating non avid smaller liver lesions which may be limited by PET 
camera’s spatial resolution.    
 
 
a. FDG PET/CT study using intravenous non ionic contrast enhanced CT 
 
 
b. FDG PET/CT study with low dose CT 
Fig. 5. Multiplanar images acquired for a 56 year old patient diagnosed with hepatocellular 
carcinoma in FDG PET/CT study using intravenous contrast (a), and using low dose CT (b). 
There are multifocal high metabolic activity lesions seen in segment VIII of the liver clearly 
demonstrate in the study as ill defined heterogenous contrast enhancement within the 
affected segment (a) as compared to low dose CT (b).   
As an alternative to using positive contrast media during PET/CT study, negative contrast 
like gas can also be used. In the assessment of intraabdominal malignancy arising from the 
bowels, cross-sectional imaging study of the bowels using CT is capable in demonstrating 
the entire intraluminal, wall thickness and extraluminal involvement (16,17).  
Non invasive virtual CT colonoscopy (VCTC) using thin-slice cross-sectional imaging 
techniques with multiplanar 3D reconstruction is another procedure capable in evaluating 
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the entire large bowel. The technique has positive impact in screening patients with 
intermediate risk for malignant colonic polyps (18,19). Integrating VCTC with FDG PET will 
perfect the diagnostic value of both modalities. This technique may be useful especially in 
the evaluation of focal increase bowel activity commonly addressed as physiological bowel 
uptake (20,21). The sensitivity and specificity of VCTC in detecting polyps ranging between 
48-85% and 91-97% depending on polyp size (Mulhall et al) while the sensitivity of FDG 
PET to detect pre-malignant adenomatous polyps also correlated with grading of polyp 
dysplasia (20) and generally non pre-malignant hyperplastic polyps do not tend to be FDG 
avid. The intensity of FDG uptake is also incapable to discriminate malignant, pre-
malignant and benign lesions (23,24). Thus incidental focal colonic uptake on PET deserves 
further confirmatory investigations to exclude a malignant pathology. CT can play an 
important role in localizing these lesions.   
The advantage of combining VCTC into FDG PET study has been proven by Veit-Haibach 
and his colleagues where the tehnique improved the accuracy of staging in 47 patients with 
colorectal carcinoma (25). 
Integrated PET/ low dose CT has limited role in local staging of rectal and colonic cancers 
except in the assessment of metastatic disease and potential recurrence (26,27) . The value of 
diagnostic CT with intravenous contrast can be optimized during integrated imaging 
PET/CT in rectal and colonic cancers especially in complicated cases of gross invasion of 
adjacent organs (T4). Contrast enhancement of the surrounding organs of the lesion can 
assess local invasion. Since CT is routinely employed as a primary tool in the detection of 
metastatic disease in rectal carcinoma, combining FDG PET and CECT will provide ‘one 
stop shop ’ for the patient (28) 
The feasible role of combined FDG PET/VCTC may also be applicable in combined FDG 
PET/CT enterography (CTE) which involves enteroclysis using low-density oral contrast 
agents , intravenous contrast and thin slice CT image acquisition. The technique can be 
useful in small bowel infections, neoplasms, adhesions, polyps, vascular malformations and 
inflammatory bowel diseases. (29) The protocol can potentially provide better clues on the 
cause of pitfalls in FDG PETCT imaging of the bowels which are currently addressed as 
physiological activity in most cases .   
The role of FDG PET / CT cholangiography using  biliary excreted contrast agent should be 
further evaluated (30)  
High resolution advanced MDCT technique has become the mainstay of pancreatic tumor 
imaging. Multiphase CT allow accurate detection, staging and assessment of tumor 
resectability (31,32). In general, the differentiation of malignant and inflammatory lesions on 
FDG PET images are crucial, Multiphase CT angiography has the potential to increase the 
diagnostic value of FDG PET/CT study in pancreatic carcinoma especially in determining 
tumour resectability by excluding vascular invasion. Contrast enhanced PET/CT is also a 
recommended imaging procedure in carcinoid and non-carcinoid neuroendocrine tumours (33).  
In any clinical situation, decision should adhere to ALARA principle. Perhaps, in view of 
clinical benefits to patients, contrast enhanced FDG PET/CT protocol should be 
recommended as a first line tool in imaging of selected malignant diseases. 
4. Implications 
4.1 Radiation dose  
Recent advances in CT equipment has enable high resolution imaging of smaller anatomical 
structures which has made imaging more feasible for small to medium size vessels but 
resulting in higher radiation dose delivered to the patients. 
www.intechopen.com
 
Computed Tomography – Clinical Applications 
 
302 
Increasing concern over radiation dose have been addressed by vendors through technical 
improvement of X-ray tubes (34). Other strategies to reduce dose include the awareness of 
referring doctors especially the capability of ‘one stop shop’ of PET CT facilities. These 
attempts to reduce patients’ radiation dose according to the ‘As Low As Reasonably 
Achievable’ (ALARA) principle(35). The opportunity to reduce dose exposure should be 
seize during whole body PET/CT study by optimizing the diagnostic role of contrasted CT. 
Each PET/CT study would lead to radiation exposure ranging from 14 to 32 mSv in adults 
depending on CT parameters. The PET component typically contributes 8–9 mSv to the 
overall radiation dose based on a standard 10mCi dose of tracer. Importantly, avoiding 
duplication of studies also reduces overall radiation exposure.  
4.2 Standardized uptake value  
Standardized uptake value (SUV) is the most commonly used method for assessing tumor 
glucose metabolism in clinical studies (36) where it can be measured with relative ease.  
The basic concept underlying the SUV is that the activity concentration after injection is 
correlated with FDG phosphorylation rates where it is approximately proportionate to the 
activity concentration in the tissue and inversely correlated to the ratio of the injected dose 
to the body weight (37).The rate of FDG phosphorylation is a measure to tumor glucose 
utilization which can be influenced by multiple factors including patient size, blood glucose 
level, extravascular injection and others (38).  
In addition to FDG PET/CT study before the start of treatment, semiquantitative analysis of 
FDG uptake is also needed in assessing early tumour response during the course of treatment 
(39,40). This can help differentiate between responders and non responders. The controversial 
effect of contrasted PET/CT study on SUV readings is highlighted in the following section.  
4.3 Effects of contrasted PET/CT on semiquantitative uptake value (SUV) 
Following the work of Kinahan and his colleagues (39), improved function of PET/CT 
scanner by CT-attenuation correction eliminated the need for orbiting transmission sources.  
The quality of joint PET/CT procedure can be improved further by performing contrast 
enhance study. Thus a separate diagnostic CT scan can be avoided.  
Studies from several groups (41,42,43,44) including Berthelsen (45) demonstrated the 
feasibility of intravenous contrast administration in PET/CT scanning without changing the 
clinical diagnostic interpretation. These studies demonstrated the effects of intravenous CT 
contrast in malignancy.   
We observed the effect of contrast CT in PET/CT study in 19 patients investigated for 
infections. In our study, whole body PET/CT scan were conducted using a standard 
protocol. Two sets of datas where low dose CT and diagnostic contrasted CT were obtained. 
Both parameters were utilized for attenuation correction of PET images. During image 
analysis, we compared the percentage difference of CT value in Hounsfield unit (HU) and 
Standardized Uptake Value (SUV) PET at 4 different anatomical sites including the right 
lobe of liver, spleen, right heart chamber and urinary bladder. We tabulated our findings 
and performed statistical analysis.  
Result 
The percentage differences of HU and SUV were calculated in all 4 different sites for all 
patients and tabulated in table 2-6. 
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Table 2. The percentage differences in HU and SUVmax and SUVmean obtained from the 
right lobe of the liver.  
 
 
 
 
Table 3. The percentage differences in HU and SUVmax and SUVmean obtained from the 
right heart chamber  
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Table 4. The percentage differences in HU and SUVmax and SUVmean obtained from the 
spleen. 
 
 
 
Table 5. The percentage differences in HU and SUVmax and SUVmean obtained from the 
bladder  
The average mean and the maximum percentage differences were calculated and tabulated 
as following:  
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Table 6. The average mean and maximum percentage differences in all sites.  
Statistical analysis   
Nineteen patients were subjected to Non-Contrast Enhanced CT (NECT), Contrast 
Enhanced CT (CECT), Non-Contrast Enhanced PET (NEPET) and Contrast Enhanced  
PET (CEPET). For analyses purpose, the clinically-relevant and quantifiable HU-Mean 
and SUV-Max were treated as unit values of observations for CT (NECT & CECT)  
and PET (NEPET & CEPET) respectively. Observations between Non-Contrast Enhanced 
and Contrast Enhanced were not treated as independent of each other because  
the changes in unit values of Contrast Enhance depended on the initial unit values  
(Non-Contrast Enhanced) of each patient. Thus, values of CT HU-Max (i.e. NECT and 
CECT) were treated as paired data. Values of PET SUV-Max (i.e. NEPET and CEPET) 
were also treated as paired data. All HU-Mean and SUV-Max values were originally 
continuous data but subsequently ranked as most did not conform to Gaussian 
distribution. Observations of NECT were compared against CECT and observations of 
NEPET were compared against CEPET. Medians and Interquartile Ranges (IQR)  
were used as summary measures for HU-Means, SUV-Maxes and percentage of change  
in HU-Means and SUV-Maxes. Non-parametric (Wilcoxon Signed Ranks) test were  
used. Alpha (α) was set at 0.05 thus statistical significance was achieved where p-value 
was less than 0.05. Summary results are shown in Table 7. Graphic comparison between 
Non-Contrast Enhanced and Contrast Enhanced observations were also shown in  
figure 6-9. 
Interpretation 
At 3 different sites (Liver, Heart & Spleen), we are able to show that the HU-Mean of Non-
Contrast Enhanced CT (NECT) differ than that of Contrast Enhanced CT (CECT). This 
difference is statistically significant, p<0.05 (Table 7). In other words, administrations of 
contrast in CT will yield higher HU-Mean values than plain CT (without contrast). In the 
liver, the median increase in HU-Mean is 75.4% (+/38.6%). Results of observations in the 
heart and spleen also showed similar trend. Only in the bladder the values of HU-Mean did 
not differ statistically (p=0.147).  
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SITE 
IMAGING TEST  
(Values Used) 
HU-Mean/SUV-Max 
% Change in  
HU-Mean/SUV-Max  p-value 
Median(IQR) Median(IQR)
LIVER 
NECT (HU-Mean), n=19 56 (13.4) 
75.4 (38.6) <0.001* 
CECT (Hu-Mean), n=19 92.4 (19.5) 
 
NEPET (SUV-Max), n=19 2.9 (1.3) 
0 (12.5) 0.814 
CEPET (SUV-Max), n=19 2.6 (1.0) 
     
HEART 
NECT (HU-Mean), n=19 47 (29.6) 
182.3 (179.2) <0.001* 
CECT (HU-Mean), n=19 130 (53.0) 
 
NEPET (SUV-Max), n=19 2.1 (0.9) 
0 (14.9) 0.876 
CEPET (SUV-Max), n=19 2 (2.2) 
     
SPLEEN 
NECT (HU-Mean), n=19 50 (16) 
96.0 (86.0) 0.001* 
CECT (HU-Mean), n=19 93.3 (22.1) 
 
NEPET (SUV-Max), n=19 2.6 (0.7) 
0 (80.0) 0.721 
CEPET (SUV-Max), n=19 2.4 (1.0) 
     
BLADDER 
NECT (HU-Mean), n=19 -1.2 (10.9) 
-110.9 (12854.4) 0.147 
CECT (HU-Mean), n=19 6.3 (27.9) 
 
NEPET (SUV-Max), n=19 6 (4.6) 
0 (9.1) 0.440 
CEPET (SUV-Max), n=19 5.3 (4.9) 
*statistically significant difference, p<0.05 (Wilcoxon Signed Ranks Test) 
Table 7. Comparing Non-Contrast Enhanced CT versus Contrast Enhanced CT and Non-
Contrast Enhanced PET versus Contrast Enhanced PET at 4 sites in 19 subjects  
On the other hand, contrast administrations apparently did not affect the results of PET as 
evidenced by its SUV-Max values. Non-contrasted PET (NEPET) and Contrasted PET 
(CEPET) yield similar values of SUV-Max (median % change in SUV-Max=0). They were not 
statistically different in the liver (p=0.814), heart (p=0.876), spleen (p=0.721) and bladder 
(p=0.44). Comparing the effects of contrasts on CT and PET can be easily seen by eyeballing. 
Thus we were able to show that contrast may change the result of CT (by increasing its HU-
Mean) but not PET (SUV-Max). How this can affect diagnosis or clinical decision is a 
question that must be explored further.  
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Fig. 6. Side-by-side box & whisker plots of HU-Mean/SUV Max distributions comparing 
Non-Contrast Enhanced (left within) and Contrast Enhanced (right within) in CT (left) and 
PET (right) of the Liver. 
 
 
 
 
 
Fig. 7. Side-by-side box & whisker plots of HU-Mean/SUV Max distributions comparing 
Non-Contrast Enhanced (left within) and Contrast Enhanced (right within) in CT (left) and 
PET (right) of the Heart. 
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Fig. 8. Side-by-side box & whisker plots of HU-Mean/SUV Max distributions comparing 
Non-Contrast Enhanced (left within) and Contrast Enhanced (right within) in CT (left) and 
PET (right) of the Spleen. 
 
 
 
 
 
Fig. 9. Side-by-side box & whisker plots of HU-Mean/SUV Max distributions comparing 
Non-Contrast Enhanced (left within) and Contrast Enhanced (right within) in CT (left) and 
PET (right) of the Bladder.  
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5. Conclusions  
In conclusion, contrast enhanced PET/CT study provide detail anatomical imaging 
descriptions obviating the need for a separate CT study and improve lesion 
characterization including surrounding organs and vascular involvement. Detail CT 
informations can be optimized and utilized in patient clinical management. Thus the 
protocol can be recommended as a first line tool in the investigation of oncology patients.   
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diagnostic tool for non- destructive material testing and three-dimensional visualization beyond its medical use.
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